Disc Medicine rallies 32% as investors await bitopertin trial results
Disc Medicine (IRON) shares jumped 32% in premarket trading on Monday ahead of topline results from its Phase 3 APOLLO trial of bitopertin, an experimental treatment for erythropoietic protoporphyria (EPP), a rare disorder that causes severe sensitivity to sunlight.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.